APR 07, 2016 7:30 AM PDT

Evidence Required by FDA for Establishing Clinical Validity

Speaker
  • Director, Office of In Vitro Diagnostics, CDRH
    Biography
      Alberto Gutierrez is the director of the Office of In Vitro Diagnostic Device Evaluation and Safety at the Food and Drug Administration. Gutierrez has had a longstanding career with the FDA, joining in 1992 as a reviewer in the FDA's Center for Biologics Evaluation and Research working on vaccine adjuvants and method development for determination of the purity and structure of vaccine components. In 2000, he joined the FDA Center for Devices and Radiological Health as a scientific reviewer, becoming a team leader for Toxicology in 2003, director of the Division of Chemistry and Toxicology Devices in 2005, deputy director of the Office of In Vitro Diagnostic Device Evaluation and Safety in 2007, and office director in 2009. He holds a bachelor's degree from Haverford College and master and doctorate degrees in chemistry from Princeton University.

    Abstract

    In this webinar the speaker discusses the approach taken by the Food and Drug administration in their pre-market review of in vitro diagnostic tests.  The legal bar passed by congress in the medical device amendment to the Federal Food and Cosmetic Act defined that the Agency needs to ascertain that there is a reasonable assurance that the device is safe and effective.  The talk explores how the FDA interprets that with respect to the analytical and clinical validity of a test and what that means in practical terms as the Agency weighs the risks and benefits of the device to make its determinations.  Two examples are put forth to show the difference between the review of a moderate risk device for which the clinical validity has been well established, and a new type of device that needs to demonstrate clinical validity.

    Learning Objectives:

    1.  To understand how the FDA evaluates in vitro diagnostic tests.
    2.  To learn the relationship between the safety and effectiveness of an in vitro diagnostic test and the test clinical validity.

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources